医学
溶栓
荟萃分析
冲程(发动机)
内科学
科克伦图书馆
观察研究
优势比
脑出血
他汀类
出版偏见
心肌梗塞
蛛网膜下腔出血
机械工程
工程类
作者
Chaohua Cui,Qiang Li,Changhong Li,Shubin Zhao,Yuchuan Li
标识
DOI:10.1016/j.jocn.2022.02.012
摘要
For ischemic stroke patients, thrombolysis therapy combined statins might have a better benefit. But difference studies had a debate. The meta-analysis wants to make clear about whether statins could increase effect of therapy or decrease side effect for these patients.To evaluate the effect and safety about using statins in ischemic stroke patients receiving thrombolysis.Databases including PubMed, Web of Science, Embase and Cochrane Library.original observational cohort studies.ischemic stroke patients receiving thrombolysis.pretreatment statins.forest plot to show pooled results; I-squared test to evaluate the heterogeneity.Of 87 selected, 8 were eligible. The 8 studies included 10,344 patients (with statins: 2048; without statins: 8296). For clinical recovery at 24 h, pooled OR (odds ratios) was 1.82 (95% CI: 1.49-2.21). For excellent outcome, pooled OR was 1.03 (95% CI: 0.80-1.12). For favorable outcome, pooled OR was 0.99 (95% CI: 0.85-1.16). For ICH (intracranial hemorrhage), pooled OR was 1.16 (95% CI: 0.97-1.40). For sICH (symptomatic intracranial hemorrhage), pooled OR was 1.40 (95% CI: 1.02-1.91). For mortality, overall pooled OR was 0.96 (95% CI: 0.74-1.25).In conclusion, the meta-analysis found that for ischemic stroke patients receiving thrombolysis, pretreatment statins were related to a better clinical recovery and a lower short-term mortality. Pretreatment statins had no significant relationship with mRS at 90 days and ICH. Pretreatment high dose statins may be related to the occurrence of sICH.
科研通智能强力驱动
Strongly Powered by AbleSci AI